ProSiebenSat.1 Media SE

  • WKN: PSM777
  • ISIN: DE000PSM7770
  • Land: Deutschland

Nachricht vom 21.01.2021 | 20:57

ProSiebenSat.1 Group exceeds expectations for revenues and adjusted EBITDA in full-year 2020 noticeably

ProSiebenSat.1 Media SE / Key word(s): Annual Results
ProSiebenSat.1 Group exceeds expectations for revenues and adjusted EBITDA in full-year 2020 noticeably

21-Jan-2021 / 20:57 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Unterfoehring, January 21, 2021. ProSiebenSat.1 Group has achieved revenues of around EUR 4.040 billion and an adjusted EBITDA of around EUR 700 million for the full-year of 2020. These figures are preliminary and unaudited. Thus, the Group has clearly exceeded its full-year financial outlook last published in the context of the Q3 2020 results release as well as market expectations. ProSiebenSat.1 had targeted Group revenues between EUR 3.85 billion and EUR 3.95 billion as well as an adjusted EBITDA between EUR 600 million and EUR 650 million in full-year 2020 after the Group's business had been heavily influenced particularly in the second quarter by the COVID-19 related restrictions.

Stefanie Rupp-Menedetter
Head of Group Communications & Events

ProSiebenSat.1 Media SE
Medienallee 7 · D-85774 Unterföhring
Phone +49 89 950 725 98
Mobil +49 17 283 527 03

21-Jan-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021